Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05002621 · ClinicalTrials.gov registry record
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 20
- Enrollment target
NCT05002621: Completed study, sponsored by Mayo Clinic.
NCT05002621 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05002621 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).
Primary Outcome
Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples for bulk RNA sequencing. Paired differential expression (DE) gene analysis was performed comparing baseline gene expression versus 12 weeks post initiation of mepolizumab.
Interventions
- OTHER Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-02-16 |
| Est. Completion | 2025-12-11 |
What the finished NCT05002621 record still lists
NCT05002621 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT05002621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05002621 about?
NCT05002621 is a clinical study titled "Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma". The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).
What is the current status of trial NCT05002621?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2021-02-16. Estimated completion is 2025-12-11.
What interventions are being tested in trial NCT05002621?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT05002621?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI